ArticleCancer reports (Hoboken, N.J.)2022

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.

Cesar Gentille et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.